Skip to content

TriangleGet started

← Full study record

NCT06655818 · OUTCOME

DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to Baseline

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM · Source last updated 2025-03-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Baseline (Day 1) and up to 153 weeks

What was measured

Blood samples were collected for the analysis of following chemistry parameters: Hypoglycemia, hypoalbuminemia, alkaline phosphatase (ALP) increased, alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatine kinase (CPK) increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hyperkalemia, blood lactate dehydrogenase (LDH) increased, hypermagnesemia, hypomagnesemia, hypernatremia, hypercalcemia, hypocalcemia and chronic kidney disease. G1: mild; G2: moderate; G3: severe. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2 and G3 are presented. The laboratory parameters were graded according to CTCAE version 5.

Analysis population: Safety Population. Only those participants with data available at the specified categories were analyzed.

Groups in this outcome

1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab

Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 500 mg dostarlimab as a 30-minute IV infusion 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles (Q3W).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Reported measurements

Hypoglycemia, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypoglycemia, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypoglycemia, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypoalbuminemia, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypoalbuminemia, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	2	Not reported	Not reported	Not reported	Not reported

Hypoalbuminemia, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Alkaline phosphatase increased, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Alkaline phosphatase increased, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Alkaline phosphatase increased, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Alanine aminotransferase increased, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	2	Not reported	Not reported	Not reported	Not reported

Alanine aminotransferase increased, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	1	Not reported	Not reported	Not reported	Not reported

Alanine aminotransferase increased, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Aspartate aminotransferase increased, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	2	Not reported	Not reported	Not reported	Not reported

Aspartate aminotransferase increased, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Aspartate aminotransferase increased, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	1	Not reported	Not reported	Not reported	Not reported

Blood bilirubin increased, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Blood bilirubin increased, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	1	Not reported	Not reported	Not reported	Not reported

Blood bilirubin increased, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

CPK increased, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	1	Not reported	Not reported	Not reported	Not reported

CPK increased, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

CPK increased, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Creatinine increased, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	2	Not reported	Not reported	Not reported	Not reported

Creatinine increased, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Creatinine increased, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

GGT increased, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	1	Not reported	Not reported	Not reported	Not reported

GGT increased, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

GGT increased, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hyperkalemia, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hyperkalemia, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hyperkalemia, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Blood lactate dehydrogenase increased, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4	Not reported	Not reported	Not reported	Not reported

Blood lactate dehydrogenase increased, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Blood lactate dehydrogenase increased, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypermagnesemia, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	1	Not reported	Not reported	Not reported	Not reported

Hypermagnesemia, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypermagnesemia, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypomagnesemia, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypomagnesemia, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypomagnesemia, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypernatremia, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypernatremia, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypernatremia, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypercalcemia, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	1	Not reported	Not reported	Not reported	Not reported

Hypercalcemia, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypercalcemia, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypocalcemia, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypocalcemia, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Hypocalcemia, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	4

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Chronic Kidney Disease, Increase to Grade 1

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Chronic Kidney Disease, Increase to Grade 2

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Chronic Kidney Disease, Increase to Grade 3

Analysis denominator · Participants

Group	Source count
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab	0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
0
denoms
counts
group Id
OG000
value
4
units
Participants
title
Hypoglycemia, Increase to Grade 1
categories
measurements
group Id
OG000
value
0
denoms
counts
group Id
OG000
value
4
units
Participants
title
Hypoglycemia, Increase to Grade 2
categories
measurements
group Id
OG000
value
0
denoms
counts
group Id
OG000
value
4
units
Participants
title
Hypoglycemia, Increase to Grade 3
categories
measurements
group Id
OG000
value
0
denoms
counts
group Id
OG000
value
4
units
Participants
title
Hypoalbuminemia, Increase to Grade 1
categories
measurements
group Id
OG000
value
2
denoms
counts
group Id
OG000
value
4
units
Participants
title
Hypoalbuminemia, Increase to Grade 2
categories
measurements
group Id
OG000
value
0
denoms
counts
group Id
OG000
value
4
units
Participants
title
Hypoalbuminemia, Increase to Grade 3
categories
measurements
group Id
OG000
value
0
denoms
counts
group Id
OG000
value
4
units
Participants
title
Alkaline phosphatase increased, Increase to Grade 1
categories
measurements
group Id
OG000
value
0
denoms
counts
group Id
OG000
value
4
units
Participants
title
Alkaline phosphatase increased, Increase to Grade 2
categories
measurements
group Id
OG000
value
0
denoms
counts
group Id
OG000
value
4
units
Participants
title
Alkaline phosphatase increased, Increase to Grade 3
categories
measurements
group Id
OG000
value
2
denoms
counts
group Id
OG000
value
4
units
Participants
title
Alanine aminotransferase increased, Increase to Grade 1
categories
measurements
group Id
OG000
value
1
denoms
counts
group Id
OG000
value
4
units
Participants
title
Alanine aminotransferase increased, Increase to Grade 2
categories
measurements
group Id
OG000
value
0
denoms
counts
group Id
OG000
value
4
units
Participants
title
Alanine aminotransferase increased, Increase to Grade 3

denoms

counts
group Id
OG000
value
4
units
Participants

description

Blood samples were collected for the analysis of following chemistry parameters: Hypoglycemia, hypoalbuminemia, alkaline phosphatase (ALP) increased, alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatine kinase (CPK) increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hyperkalemia, blood lactate dehydrogenase (LDH) increased, hypermagnesemia, hypomagnesemia, hypernatremia, hypercalcemia, hypocalcemia and chronic kidney disease. G1: mild; G2: moderate; G3: severe. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2 and G3 are presented. The laboratory parameters were graded according to CTCAE version 5.

groups

description
Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 500 mg dostarlimab as a 30-minute IV infusion 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles (Q3W).
id
OG000
title
1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab

param Type

COUNT_OF_PARTICIPANTS

population Description

Safety Population. Only those participants with data available at the specified categories were analyzed.

reporting Status

POSTED

time Frame

Baseline (Day 1) and up to 153 weeks

title

DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to Baseline

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice